What the FDA labels say about taking them together
Digoxin and risperidone
Risperidone's FDA label of May 28, 2026 names digoxin in its drug interactions section; the digoxin labels PlainMeds reads (3) do not name risperidone. The risperidone label: “Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS).”
Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the risperidone FDA label on DailyMed (effective May 28, 2026, Janssen Pharmaceuticals, Inc.).
What does the digoxin label say about risperidone?
Digoxin's label (effective December 5, 2024) and its 2 other brand-application labels do not name risperidone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
What does the risperidone label say about digoxin?
Risperidone label, drug interactionsDigoxin RISPERDAL (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin. Dose adjustment for digoxin is not recommended.
Rykindo Extended-Release Microspheres label (Shandong Luye Pharmaceutical Co., Ltd., May 26, 2026), drug interactionsClinical Impact: Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS). … inhibitors (erythromycin). Additionally, no dosage adjustment is necessary for lithium, valproate, topiramate, digoxin and CYP2D6 substrates (donepezil and galantamine) when co-administered with RYKINDO [ see Clinical Pharmacology (12.3) ].
Source: FDA drug label (Risperdal Consta, NDA021346), Janssen Pharmaceuticals, Inc., effective November 5, 2025 (SPL set bb34ee82-d2c2-43b8-ba21-2825c0954691), via openFDA
Source: FDA drug label (Rykindo Extended-Release Microspheres, NDA212849), Shandong Luye Pharmaceutical Co., Ltd., effective May 26, 2026 (SPL set 58534c96-96f5-4c2e-a061-92d4506aee91), via openFDA
Source: FDA drug label (Risperidone, NDA020588), Janssen Pharmaceuticals, Inc., effective August 20, 2026 (SPL set 701e1cd8-2868-4d29-85a9-a2212c88165f), via openFDA
Source: FDA drug label (RISPERDAL), Janssen Pharmaceuticals, Inc., effective May 28, 2026 (SPL set 7e117c7e-02fc-4343-92a1-230061dfc5e0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Digoxin | Risperidone | |
|---|---|---|
| Labeled for | Heart failure, Atrial fibrillation | Bipolar disorder, Schizophrenia |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.133 per tablet 125 mcg tablet | $0.0368 per tablet 0.25 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once